Cadila Healthcare is currently trading at Rs. 356.35, up by 7.70 points or 2.21% from its previous closing of Rs. 348.65 on the BSE.
The scrip opened at Rs. 346.05 and has touched a high and low of Rs. 359.85 and Rs. 346.05 respectively. So far 38080 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 341.65 on 22-May-2018.
Last one week high and low of the scrip stood at Rs. 371.55 and Rs. 344.15 respectively. The current market cap of the company is Rs. 36409.41 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.64% and 8.40% respectively.
United States Food and Drug Administration (USFDA) has inspected Zydus Cadila’s wholly owned subsidiary, Alidac Pharmaceuticals’ manufacturing facility located at SEZ in Ahmedabad from May, 28 to June, 5 2018. At the end of the inspection there was no observation (483) issued. The site manufactures oncology injectables for the regulated markets.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.35 |
Dr. Reddys Lab | 5811.90 |
Cipla | 1406.45 |
Zydus Lifesciences | 1000.85 |
Lupin | 1670.05 |
View more.. |